相关实验视频

Updated: Jan 12, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

达托帕马布德鲁克斯泰坎:转移性乳腺癌向治疗的新时代

Maryam Mobashir¹, Huda Tarique², Shakeel Ahmad³

¹Department of Medicine, Dow University of Health and Sciences, Karachi, Pakistan.

Annals of medicine and surgery (2012)

|November 3, 2025

概括

达托帕马布德鲁克斯泰坎 (Dato-DXd) 是FDA批准的治疗HR+,HER2转移性乳腺癌的药物. 它表现出比化疗更高的疗效,为患者提供了一种新的选择,这些患者对以前的疗法有抗性.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
免疫治疗是一种免疫疗法.

背景情况:

激素受体阳性 (HR+),人体表皮生长因子受体2-阴性 (HER2-) 转移性乳腺癌仍然是一个重大的临床挑战.
现有的治疗方法,包括内分泌疗法和化疗,在疗效和抗药性发展方面存在局限性.
对于新的治疗策略来改善这些患者的治疗结果是非常需要的.

研究的目的:

审查dato-DXd的作用机制,临床疗效和安全性.
评估Dato-DXd在当前乳腺癌治疗算法中的位置.
为了比较Dato-DXd与其他抗体药物联合体,如trastuzumab deruxtecan (T-DXd).

主要方法:

对临床前数据和临床试验结果的审查 (例如,TROPION-Breast01研究).
对药物-抗体结合技术的分析,包括链接器化学和有效载荷释放.
对TROP2向和抗体-药物合物内部化的药理学评估.

主要成果:

在TROPION-Breast01研究中,与传统化疗相比,达托帕马布德鲁克斯泰康的疗效更高.
达托-DXd为HR+,HER2转移性乳腺癌患者提供了可行的替代方案,这些患者在之前的治疗中进展.
抗体 - 药物结合机制涉及TROP2介导的内部化和细胞毒性有效载荷DXd的有针对性的释放.

结论:

达托帕马布德鲁克斯泰坎在治疗HR+,HER2转移性乳腺癌方面取得了重大进展.
达托-DXd提供了一个有前途的治疗选择,与传统化疗相比,其疗效提高了.
进一步的研究和临床试验对于充分阐明Dato-DXd和T-DXd在乳腺癌治疗模式中的作用至关重要.

关键词:

乳腺癌乳腺癌乳腺癌数据库 Deruxtecan 的数据库.转移性癌症转移性癌症是一种转移性癌症.瘤学在瘤学方面.有针对性的治疗.

更多相关视频

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.